Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSI-7904L vs 5-FU/LV in advanced biliary tract cancer
NCT00088270Phase 2Completed
- Sponsor
- OSI Pharmaceuticals
- Start
- Aug 2004
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of OSI-7904L in biliary tract cancer (BTC) (2 arms), sponsored by OSI Pharmaceuticals. Primary endpoint: Objective Response Rate. Started Aug 2004; status: completed.
02
Drugs
OSI-7904L
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT00088270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088270.